Bayer Sues Mylan Over Generic Yaz

Law360, New York (April 20, 2011, 6:05 PM EDT) -- Bayer AG filed a patent infringement suit Monday in Nevada federal court against Mylan Pharmaceuticals Inc. over the generics maker’s bid to sell a version of oral contraceptive Yaz in the U.S.

Continuing its efforts to block a generic version of Yaz from hitting the U.S. market, Bayer alleges that Mylan’s proposed product would infringe one or more claims of U.S. Patent Number RE37,564.

Yaz, a combination of drospirenone and ethinyl estradiol, is marketed as the only oral contraceptive also approved by the FDA to treat...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.